ClinicalTrials.gg
CompletedNCT01130337Updated Oct 1, 2015Results posted

A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

A Phase 2 interventional study of Capecitabine [Xeloda] and Oxaliplatin in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 30 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-01.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.

Enrollment
68th of 97
36 · median 50
Started
2010
with 6 others
Phase 2
58 of 100
4 open now
Registered
49th of 100
by date
Lead sponsor
5 of 100
Hoffmann-La Roche

Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 68th largest by enrollment of the 97 interventional ones that give a count, is one of 7 that started in 2010, is one of 58 in phase 2, and was the 49th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing capecitabine in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer. The combination of Xeloda (orally, 1000 mg/m2 on day 1-14 of every cycle) and Herceptin (intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1-14 of every cycle) will be administered for three cycles prior to surgery to resect the tumor. If complete resection, R0 or microscopic residual tumor R1 is achieved, patients will continue with three cycles of XELOX and Herceptin and then for completion of 12 months treatment with Herceptin alone. Oxaliplatin will be administered intravenously at a dose of 130 mg/m2 on day 1 in every cycle. The anticipated time on study drug will be 12 months.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over 18 years of age
  • Locally advanced resectable -positive gastric or esophagogastric junction adenocarcinoma (Sievert types I, II, III)
  • Measurable ( criteria) or assessable disease
  • performance 0-2
  • of 12 weeks or more

Exclusion criteria

Exclusion Criteria:

  • Immeasurable lesion as the only evidence of disease
  • Previous chemotherapy or radiotherapy for gastric neoplasm or some kind of previous surgical resection of the tumor (except diagnostic laparoscopy)
  • Concomitant heart disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    1

    Drug: Capecitabine [Xeloda] · Drug: Oxaliplatin · Drug: Trastuzumab [Herceptin]

Interventions

  • 1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles

  • 130 mg/m2 intravenous infusion day 1 of every cycle

  • First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease-free Survival (DFS) at Month 18

    DFS was the time elapsed from the time of surgery (for complete resection \[R0\] participants) until the date on which progression or death from any cause was documented (whichever occured first). Progression was defined as target lesions greater than (\>) 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded since the treatment started (nadir) and minimum 5 millimeter (mm) increase over the nadir. When the sum becomes very small, increases within the measurement error (2-3 mm) can lead to a 20% increase. Participants who did not present progression and who had not died were censored on the last date on which it was known that there was no progression (last response assessment).

    Time frame: Month 18

Secondary outcomes

  1. Percentage of Participants With Pathological Complete Response (pCR)

    pCR was defined as an absence of any invasive cancer cell of the primary tumor after the time of major neoadjuvant chemotherapy, with or without surgery.

    Time frame: Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25

  2. Percentage of Participants With Complete Tumor Resection (R0)

    R0 resection was defined as having performed a complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation.

    Time frame: Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25

  3. Percentage of Participants With Objective Response

    An objective response was defined as either a complete response (CR) or a partial response (PR). Using the Response Evaluation Criteria in Solid Tumors (RECIST), CR was defined as the disappearance of all target lesions and all non-target lesions, normalization of tumor marker level, and no new lesions. PR was defined as the disappearance of all target lesions and persistence of greater than or equal to (≥) 1 non-target lesions and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing non-target lesions.

    Time frame: Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25

07

Results

Posted Oct 1, 2015

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine+Oxaliplatin+Trastuzumab
Started36
Completed22
Not completed14
Withdrew: Withdrawal by subject3
Withdrew: Principal investigator decision1
Withdrew: Death1
Withdrew: Disease progression1
Withdrew: Toxicity, ae/intercurrent disease7
Withdrew: Surgical resection (r2)1

Outcome measures

PrimaryPercentage of Participants With Disease-free Survival (DFS) at Month 18

DFS was the time elapsed from the time of surgery (for complete resection \[R0\] participants) until the date on which progression or death from any cause was documented (whichever occured first). Progression was defined as target lesions greater than (\>) 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded since the treatment started (nadir) and minimum 5 millimeter (mm) increase over the nadir. When the sum becomes very small, increases within the measurement error (2-3 mm) can lead to a 20% increase. Participants who did not present progression and who had not died were censored on the last date on which it was known that there was no progression (last response assessment).

Time frame:
Month 18
Reported as:
Number · percentage of participants
Percentage of Participants With Disease-free Survival (DFS) at Month 18
percentage of participantsCapecitabine+Oxaliplatin+Trastuzumab
Percentage of Participants With Disease-free Survival (DFS) at Month 1876.12 (57.72 to 87.32)
SecondaryPercentage of Participants With Pathological Complete Response (pCR)

pCR was defined as an absence of any invasive cancer cell of the primary tumor after the time of major neoadjuvant chemotherapy, with or without surgery.

Time frame:
Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological Complete Response (pCR)
percentage of participantsCapecitabine+Oxaliplatin+Trastuzumab
Percentage of Participants With Pathological Complete Response (pCR)8.33 (1.75 to 22.47)
SecondaryPercentage of Participants With Complete Tumor Resection (R0)

R0 resection was defined as having performed a complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation.

Time frame:
Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Tumor Resection (R0)
percentage of participantsCapecitabine+Oxaliplatin+Trastuzumab
Percentage of Participants With Complete Tumor Resection (R0)90.32 (74.25 to 97.96)
SecondaryPercentage of Participants With Objective Response

An objective response was defined as either a complete response (CR) or a partial response (PR). Using the Response Evaluation Criteria in Solid Tumors (RECIST), CR was defined as the disappearance of all target lesions and all non-target lesions, normalization of tumor marker level, and no new lesions. PR was defined as the disappearance of all target lesions and persistence of greater than or equal to (≥) 1 non-target lesions and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing non-target lesions.

Time frame:
Between Days 7 and 21 of the 3rd cycle of neoadjuvant treatment, thereafter, every 9 weeks during adjuvant treatment and then after adjuvant treatment every 3 months until Month 25
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response
percentage of participantsCapecitabine+Oxaliplatin+Trastuzumab
Percentage of Participants With Objective Response38.89

Adverse events

Collected over Before Day 1 of each cycle until Month 25. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine+Oxaliplatin+Trastuzumab—22/36 (61.1%)35/36 (97.2%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventCapecitabine+Oxaliplatin+Trastuzumab
DiarrhoeaGastrointestinal disorders5/36
Localised intra-abdominal fluid collectionGastrointestinal disorders2/36
PneumoniaInfections and infestations2/36
PneumothoraxRespiratory, thoracic and mediastinal disorders2/36
Cardiogenic shockCardiac disorders1/36
DysphagiaGastrointestinal disorders1/36
Intestinal ischaemiaGastrointestinal disorders1/36
Intestinal obstructionGastrointestinal disorders1/36
Oesophageal perforationGastrointestinal disorders1/36
VomitingGastrointestinal disorders1/36
Most frequent other events
Showing 10 of 41
Most frequent other events
EventCapecitabine+Oxaliplatin+Trastuzumab
DiarrhoeaGastrointestinal disorders29/36
AstheniaGeneral disorders24/36
NauseaGastrointestinal disorders17/36
VomitingGastrointestinal disorders15/36
Decreased appetiteMetabolism and nutrition disorders15/36
AnaemiaBlood and lymphatic system disorders11/36
PyrexiaGeneral disorders10/36
NeurotoxicityNervous system disorders10/36
Abdominal painGastrointestinal disorders9/36
Mucosal inflammationGeneral disorders8/36

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Capecitabine+Oxaliplatin+Trastuzumab
Mean63.44 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine+Oxaliplatin+Trastuzumab
Female7
Male29
08

Study locations

30 sites
  • Elche, Alicante 03203, Spain
  • Oviedo, Asturias 33006, Spain
  • Santander, Cantabria 39008, Spain
  • San Sebastian, Guipuzcoa 20014, Spain
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • Vigo, Pontevedra 36204, Spain
  • La Laguna, Tenerife 38320, Spain
  • Barakaldo, Vizcaya 48903, Spain
  • Barcelona, 08003, Spain
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Barcelona, 08907, Spain
  • Barcelona, 08916, Spain
  • Burgos, 09006, Spain
  • Cordoba, 14004, Spain
  • Granada, 18014, Spain
  • La Coruña, 15006, Spain
  • Leon, 24071, Spain
  • Lerida, 25198, Spain
  • Lugo, 27003, Spain
  • Madrid, 28007, Spain
  • Madrid, 28040, Spain
  • Madrid, 28041, Spain
  • Orense, 32005, Spain
  • Sevilla, 41013, Spain
  • Sevilla, 41014, Spain
  • Toledo, 45004, Spain
  • Valencia, 46009, Spain
  • Valencia, 46014, Spain
  • Zaragoza, 50009, Spain
09

References and documents

Publications

  • Rivera F, Izquierdo-Manuel M, Garcia-Alfonso P, Martinez de Castro E, Gallego J, Limon ML, Alsina M, Lopez L, Galan M, Falco E, Manzano JL, Gonzalez E, Munoz-Unceta N, Lopez C, Aranda E, Fernandez E, Jorge M, Jimenez-Fonseca P. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021 Mar;145:158-167. doi: 10.1016/j.ejca.2020.12.005. Epub 2021 Jan 20. PubMed 33485079 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
May 26, 2010
Start
Jul 2010
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Oct 1, 2015
Last update
Oct 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01130337
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 26, 2010
Start date
Jul 2010
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Oct 1, 2015
Last update
Oct 1, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Oxaliplatin · Trastuzumab

Start the discussion